@FierceBiotech: First "cross-kingdom" vaccine effective in Phase I. Report | Follow @FierceBiotech
@RyanMFierce: Check out Mark Leuchtenberger's scheduled IPO for Rib-X, an antibiotics developer, after price cut. More | Follow @RyanMFierce
> The FDA and EMA have accepted Biogen Idec's ($BIIB) applications for multiple sclerosis pill BG-12. The FDA granted a standard review for the drug, which Biogen aims to launch on the U.S. market next year. Item
> U.S. regulators have given a green light for three patients with ALS to receive a second dose of stem cells after the first dose was given to patients safely. Release
> Pulmotect has pulled in a $7.1 million grant from the Cancer Prevention & Research Institute of Texas to study a product for protecting patients on chemotherapy from infections. Announcement
Pharma News
@FiercePharma: Here's Glaxo's take on the official launch of hostile HGS bid. More | Follow @FiercePharma
> DSM panel holds firm on new autism diagnosis, ditches 2 other revisions. News
> With generics horde advancing, Pfizer gives up Lipitor push. Report
> Roche's Tarceva wins NICE nod for first-line use. Article
> Glaxo can nail HGS buy with slightly bigger bid, analysts say. Item
Medical Devices News
@FierceMedDev: Finland's ArcDia grabs $3.5M in new financing to fuel growth of its respiratory infection diagnostic test. Item | Follow @FierceMedDev
> FDA looks to reduce kids' radiation exposure in draft guidance. News
> George Will jumps on the anti-device tax bandwagon. Article
> Report: Bad lifestyles fuel diagnostics boom in emerging markets. Story
> Study: Worriers, negative folks fair worse with ICDs. Report
CRO News
@NesaNFierce: Monkey see, monkey ... don't. MPI Research is getting lots of flack from the USDA and an animal rights group over animal mistreatment. Article | Follow @NesaNFierce
> CMO service pacts needed for success, Baxter says. News
> Kythera seeks $250,000 from Cetero for development delays. Story
> AMRI sees Q1 drops, but maintains positive financial outlook for 2012. More
> Covance sees early development losses, closes Arizona lab. Item
Pharma Manufacturing News
@EricPFierce: Ranbaxy's stellar first quarter shows the upside of having pharma manufacturing operations tip top. Report | Follow @EricPFierce
> 12-year-old consent decree lifted from Abbott. Story
> FDA critical of Genentech's Avastin production. Article
> Pfizer may announce $129M expansion in Belgium. More
> Patheon exiting most manufacturing at U.K. plant. Item
Vaccines News
> MMR and autism: Italy's courts get involved. Report
> Study: Further insight into Merck HIV vax infection increase. Article
> Pneumococcal vax cuts deaths, but cases tripled. News
> Swine flu vax could offer universal flu protection. Story
And Finally… A cell therapy reversed Type 1 diabetes in a mouse study, giving researchers hope for a cure in humans. Item